FUTIBATINIB

Delivery:
oral
Indication:
cholangiocarcinoma second line therapy (pivotal phase 2)
Locations:
US EU JP

Fibroblast growth factor receptor (FGFR) 1-4 inhibitor

Link to clinicaltrials.gov